Accuray, a medical device manufacturer based in Sunnyvale, California, received 510(k) FDA clearance for the newest generation of its CyberKnife system. The CyberKnife M6 is used for radiosurgery. According to a press release, Accuray plans to launch the next-gen CyberKnife immediately.
The new CyberKnife M6 radiosurgery device has several advantages over similar products. Many traditional radiosurgery devices use a targeted beam of radiation that must remain static to destroy cancerous cells in the body. Since body movement can impact the efficacy of static radiosurgery systems, they may not be appropriate for all patients. The CyberKnife M6 radiosurgery device is designed to continually monitor body movements and adjusts automatically to maintain a lock on cancerous tumors.
Chief commercial officer of Accuray, Kelly Londy, shared information on the CyberKnife system in a press release. "We're really confident in CyberKnife being the only system on the market to track and correct automatically through the treatment plan.” She continued, "It actually tracks the tumor as it moves. The robot can move in any direction, so it tracks and adjusts as the organ is shifting."
The CyberKnife M6 is also designed for sterotactic body radiation therapy and stereotactic radiosurgery. This gives the device a higher potential market share than many other radiosurgery systems currently available. According to information from CCO Kelly Londy, the 510(k) clearance lets the device be used for many different forms of cancer.